PE20180231A1 - Compuestos nucleosidos 5'-sustituidos - Google Patents
Compuestos nucleosidos 5'-sustituidosInfo
- Publication number
- PE20180231A1 PE20180231A1 PE2017002330A PE2017002330A PE20180231A1 PE 20180231 A1 PE20180231 A1 PE 20180231A1 PE 2017002330 A PE2017002330 A PE 2017002330A PE 2017002330 A PE2017002330 A PE 2017002330A PE 20180231 A1 PE20180231 A1 PE 20180231A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- cancer
- substituted
- nucleosid
- cyclopropoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a un compuesto de formula (I), donde: R1a es ciclopropoxi; R1b es cloro; R2 es hidrogeno y R3 es amino. Estos compuestos son nucleosidos 5'-sustituidos, composiciones farmaceuticas que comprenden los compuestos. Tambien se refiere a metodos de utilizacion de los compuestos para tratar el cancer, en particular glioblastomas, melanoma, sarcomas, cancer gastrico, cancer de pancreas, colangiocarcinoma, cancer de vejiga, cancer de mama, cancer de pulmon de celulas no pequenas, leucemias que incluyen leucemia mieloide aguda y linfomas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382225 | 2015-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180231A1 true PE20180231A1 (es) | 2018-01-31 |
Family
ID=53177322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017002330A PE20180231A1 (es) | 2015-05-04 | 2016-04-27 | Compuestos nucleosidos 5'-sustituidos |
Country Status (25)
Country | Link |
---|---|
US (1) | US9840532B2 (es) |
EP (1) | EP3292128A1 (es) |
JP (2) | JP6181889B1 (es) |
KR (1) | KR20170132871A (es) |
CN (1) | CN107580602A (es) |
AR (1) | AR104326A1 (es) |
AU (1) | AU2016258485A1 (es) |
BR (1) | BR112017020336A2 (es) |
CA (1) | CA2981097A1 (es) |
CL (1) | CL2017002637A1 (es) |
CO (1) | CO2017010727A2 (es) |
CR (1) | CR20170443A (es) |
DO (1) | DOP2017000255A (es) |
EA (1) | EA201792169A1 (es) |
EC (1) | ECSP17072987A (es) |
HK (1) | HK1244007A1 (es) |
IL (1) | IL254409A0 (es) |
MA (1) | MA42036A (es) |
MX (1) | MX2017014001A (es) |
PE (1) | PE20180231A1 (es) |
PH (1) | PH12017502002A1 (es) |
SG (1) | SG11201708345XA (es) |
TN (1) | TN2017000459A1 (es) |
TW (1) | TWI615400B (es) |
WO (1) | WO2016178870A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016135582A1 (en) * | 2015-02-24 | 2016-09-01 | Pfizer Inc. | Substituted nucleoside derivatives useful as anticancer agents |
JP7043080B2 (ja) * | 2017-01-27 | 2022-03-29 | 国立大学法人 宮崎大学 | がんに対する有効性判定キット及びがんに対する有効性判定方法 |
WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
US11220524B2 (en) | 2017-02-20 | 2022-01-11 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
UA126481C2 (uk) * | 2017-08-09 | 2022-10-12 | Прел'Юд Терап'Ютікс, Інкорпорейтід | Селективний інгібітор протеїнової аргінінметилтрансферази 5 (prmt5) |
CA3079545A1 (en) * | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
CU24621B1 (es) | 2017-12-13 | 2022-09-08 | Lupin Ltd | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 |
DK3765461T3 (da) | 2018-03-14 | 2023-11-20 | Prelude Therapeutics Inc | Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere |
US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
US20210309687A1 (en) * | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
EP3980417B1 (en) | 2019-06-10 | 2023-09-27 | Lupin Limited | Prmt5 inhibitors |
EP4048270A1 (en) | 2019-10-22 | 2022-08-31 | Lupin Limited | Pharmaceutical combination of prmt5 inhibitors |
EP4069698A1 (en) | 2019-12-03 | 2022-10-12 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL147908A0 (en) * | 1999-08-27 | 2002-08-14 | Icn Pharmaceuticals | PYRROLO[2,3-d] PYRIMIDINE NUCLEOSIDE ANALOGS |
NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
US9416154B2 (en) * | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
CA2894230A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Methods of inhibiting prmt5 |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
US9745291B2 (en) | 2012-12-21 | 2017-08-29 | Epizyme, Inc. | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
JP2016505001A (ja) * | 2012-12-21 | 2016-02-18 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
WO2016135582A1 (en) * | 2015-02-24 | 2016-09-01 | Pfizer Inc. | Substituted nucleoside derivatives useful as anticancer agents |
-
2016
- 2016-04-20 AR ARP160101081A patent/AR104326A1/es unknown
- 2016-04-22 TW TW105112724A patent/TWI615400B/zh not_active IP Right Cessation
- 2016-04-27 CA CA2981097A patent/CA2981097A1/en not_active Abandoned
- 2016-04-27 JP JP2016575652A patent/JP6181889B1/ja not_active Expired - Fee Related
- 2016-04-27 SG SG11201708345XA patent/SG11201708345XA/en unknown
- 2016-04-27 AU AU2016258485A patent/AU2016258485A1/en not_active Abandoned
- 2016-04-27 BR BR112017020336-7A patent/BR112017020336A2/pt not_active Application Discontinuation
- 2016-04-27 US US15/139,370 patent/US9840532B2/en not_active Expired - Fee Related
- 2016-04-27 EP EP16720676.2A patent/EP3292128A1/en not_active Withdrawn
- 2016-04-27 KR KR1020177031713A patent/KR20170132871A/ko active Search and Examination
- 2016-04-27 EA EA201792169A patent/EA201792169A1/ru unknown
- 2016-04-27 CR CR20170443A patent/CR20170443A/es unknown
- 2016-04-27 TN TNP/2017/000459A patent/TN2017000459A1/en unknown
- 2016-04-27 MA MA042036A patent/MA42036A/fr unknown
- 2016-04-27 PE PE2017002330A patent/PE20180231A1/es not_active Application Discontinuation
- 2016-04-27 WO PCT/US2016/029475 patent/WO2016178870A1/en active Application Filing
- 2016-04-27 MX MX2017014001A patent/MX2017014001A/es unknown
- 2016-04-27 CN CN201680025080.3A patent/CN107580602A/zh active Pending
-
2017
- 2017-02-15 JP JP2017025494A patent/JP2017125029A/ja active Pending
- 2017-09-11 IL IL254409A patent/IL254409A0/en unknown
- 2017-10-17 CL CL2017002637A patent/CL2017002637A1/es unknown
- 2017-10-20 CO CONC2017/0010727A patent/CO2017010727A2/es unknown
- 2017-10-30 DO DO2017000255A patent/DOP2017000255A/es unknown
- 2017-11-01 EC ECIEPI201772987A patent/ECSP17072987A/es unknown
- 2017-11-03 PH PH12017502002A patent/PH12017502002A1/en unknown
-
2018
- 2018-03-15 HK HK18103599.9A patent/HK1244007A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017125029A (ja) | 2017-07-20 |
AU2016258485A1 (en) | 2017-10-12 |
JP6181889B1 (ja) | 2017-08-16 |
CO2017010727A2 (es) | 2018-01-31 |
WO2016178870A1 (en) | 2016-11-10 |
JP2017525667A (ja) | 2017-09-07 |
BR112017020336A2 (pt) | 2019-05-14 |
MX2017014001A (es) | 2018-03-16 |
CA2981097A1 (en) | 2016-11-10 |
EP3292128A1 (en) | 2018-03-14 |
CR20170443A (es) | 2017-11-07 |
ECSP17072987A (es) | 2018-02-28 |
HK1244007A1 (zh) | 2018-07-27 |
IL254409A0 (en) | 2017-11-30 |
AR104326A1 (es) | 2017-07-12 |
TWI615400B (zh) | 2018-02-21 |
TW201712022A (zh) | 2017-04-01 |
EA201792169A1 (ru) | 2018-03-30 |
SG11201708345XA (en) | 2017-11-29 |
CN107580602A (zh) | 2018-01-12 |
US20160326208A1 (en) | 2016-11-10 |
MA42036A (fr) | 2018-03-14 |
KR20170132871A (ko) | 2017-12-04 |
PH12017502002A1 (en) | 2018-03-26 |
CL2017002637A1 (es) | 2018-04-20 |
US9840532B2 (en) | 2017-12-12 |
DOP2017000255A (es) | 2018-01-15 |
TN2017000459A1 (en) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180231A1 (es) | Compuestos nucleosidos 5'-sustituidos | |
AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
PH12015501934A1 (en) | New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
PH12017502334A1 (en) | Polycyclic amide derivative as cdk9 inhibitors | |
DOP2022000172A (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
CL2017000507A1 (es) | Derivados de benzodiazepina citotóxicos | |
CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
PE20170678A1 (es) | Composiciones novedosas, usos y metodos para hacerlas | |
ECSP17020172A (es) | Inhibidores de histona desmetilasa | |
BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
CU23853B1 (es) | Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2 | |
MX2020003921A (es) | Proceso para producir compuestos de tipo piridazinona herbicidas. | |
SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
JOP20190163B1 (ar) | منشط nrf2 | |
AR106958A1 (es) | Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne | |
MX2020003922A (es) | Proceso para producir compuestos de piridazinona herbicida. | |
PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |